Glaxosmi. Pharma

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE159A01016
  • NSEID: GLAXO
  • BSEID: 500660
INR
2,732.50
17.85 (0.66%)
BSENSE

Nov 20

BSE+NSE Vol: 95.11 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Ajanta Pharma
Acutaas Chemical
Gland Pharma
Emcure Pharma
Ipca Labs
Sai Life
Anthem Bioscienc
Glaxosmi. Pharma
Wockhardt
Abbott India
Biocon
Why is Glaxosmithkline Pharmaceuticals Ltd ?
1
High Management Efficiency with a high ROE of 63.44%
2
Company has a low Debt to Equity ratio (avg) at 0 times
3
Poor long term growth as Net Sales has grown by an annual rate of 4.14% and Operating profit at 13.69% over the last 5 years
4
Positive results in Sep 26
  • ROCE(HY) Highest at 80.20%
  • NET SALES(Q) Highest at Rs 1,183.57 cr
  • PBDIT(Q) Highest at Rs 402.07 cr.
5
Stock is technically in a Bullish range
  • The technical trend has improved from Mildly Bullish on 20-Nov-26
  • Multiple factors for the stock are Bullish like MACD, Bollinger Band and OBV
6
With ROE of 60.2, it has a Very Expensive valuation with a 24.7 Price to Book Value
  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 8.92%, its profits have risen by 18.9% ; the PEG ratio of the company is 2.2
7
Increasing Participation by Institutional Investors
  • Institutional investors have increased their stake by 0.64% over the previous quarter and collectively hold 13.23% of the company
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Glaxosmi. Pharma should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Glaxosmi. Pharma for you?

Medium Risk, High Return

Absolute
Risk Adjusted
Volatility
Glaxosmi. Pharma
8.92%
0.32
27.65%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
4.14%
EBIT Growth (5y)
13.69%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-1.16
Sales to Capital Employed (avg)
1.93
Tax Ratio
26.26%
Dividend Payout Ratio
93.21%
Pledged Shares
0
Institutional Holding
13.23%
ROCE (avg)
-338.63%
ROE (avg)
63.44%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
41
Industry P/E
40
Price to Book Value
24.72
EV to EBIT
32.69
EV to EBITDA
31.21
EV to Capital Employed
-148.58
EV to Sales
10.66
PEG Ratio
2.17
Dividend Yield
2.08%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
60.25%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

13What is working for the Company
ROCE(HY)

Highest at 80.20%

NET SALES(Q)

Highest at Rs 1,183.57 cr

PBDIT(Q)

Highest at Rs 402.07 cr.

PBT LESS OI(Q)

Highest at Rs 386.56 cr.

PAT(Q)

Highest at Rs 335.88 cr.

EPS(Q)

Highest at Rs 19.83

-1What is not working for the Company
CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 694.52 cr

Loading Valuation Snapshot...
Here's what is working for Glaxosmi. Pharma
Net Sales - Quarterly
Highest at Rs 1,183.57 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 402.07 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 386.56 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 386.56 cr has Grown at 20.5% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 320.87 Cr
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 335.88 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 335.88 cr has Grown at 27.6% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 263.23 Cr
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 19.83
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Here's what is not working for Glaxosmi. Pharma
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 694.52 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Non Operating Income - Quarterly
Highest at Rs 72.78 cr
in the last five quarters
MOJO Watch
Increased income from non business activities may not be sustainable

Non Operating Income